To the Editor: We share many of the concerns regarding the need for proper oversight in conducting and transparency in reporting the results of human studies expressed in the Editorial by Drs Fergusson and McIntyre.1 We agree with them and with Dr Natanson and colleagues2 that some of the large clinical HBOC trials might have been halted if the results of previous animal and human studies showing risk were known. However, we feel that the Editorial did not put into proper perspective the risk associated with allogeneic blood transfusion.
Sarani B, Gracias V. Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death. JAMA. 2008;300(11):1295-1299. doi:10.1001/jama.300.11.1297-b